Product liability litigation regularly involves the highest stakes in cases of extreme complexity. Faced with such franchise-threatening matters, the world’s leading corporations trust Paul, Weiss to lead them to victory. Our superior ability to establish a winning, long-term strategy, our unique skill at breaking down and presenting complicated material, and our vaunted trial prowess make us counsel of choice in many of the most important product liability lawsuits.
As reported by Thomson Reuters and Law.com, Paul, Weiss client Pfizer Inc. achieved a major victory when a federal court granted the company's motion for summary judgment in In Re Pfizer Inc. Securities Litigation, a securities class action filed in the United States District Court for the Southern District of New York involving decade-old disclosures related to Celebrex and Bextra. The order dismisses the case in its entirety.
The ruling by U.S. District Judge Laura Taylor Swain came ahead of a September 9 trial in the case, which investors launched in 2004, and followed an earlier ruling precluding testimony by the plaintiff's damages expert.July 8, 2014